Back to Treatments

Treatment

Enfortumab Vedotin (Padcev)

1
Conditions
19
Trials
2,000
Participants
40%
Average Safety

Condition Evidence

Bladder cancer

19 trials · 2,000 participants

70% effectiveness · 40% safety
Enfortumab Vedotin (Padcev) | DFDA